MSB 3.21% $1.13 mesoblast limited

Ann: FDA Notifies Clinical Data Sufficient for Refiling aGVHD BLA, page-557

  1. 4,194 Posts.
    lightbulb Created with Sketch. 5493
    Remember, at the time the original BLA was lodged, there was no 12 month, 2 year or 4 year mortality data available.

    So the correlation that has occurred post the fact and with alternate matrix' are also being applied to data which simply was not available at all at the time of the original BLA, and so analysis of the new data, and these new results had not occurred when the original BLA was lodged. ( Company had nothing to hide as it could not of had the information itself at that point ), particularly the longer term survival data ( 2 & + years )


 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.